AstraZeneca_NNP Annual_JJ Report_NNP and_CC Financial_NNP Statements_NNP 70_CD Form_NN 20-F_JJ Information_NN 2003_CD Notes_NNS to_TO the_DT Financial_NNP Statements_NNP continued_VBD 3_CD Exceptional_JJ items_NNS 2003 2002 2001_CD $_$ m_CD $_$ m_CD $_$ m_CD Accrual_NNP related_VBN to_TO Zoladex_NNP investigation_NN 350_CD Integration_NNP and_CC synergy_NN costs_NNS 202_CD Exceptional_JJ items_NNS included_VBN in_IN operating_NN profit_NN 350_CD 202_CD Profit_NN on_IN sale_NN of_IN fixed_JJ assets_NNS 10_CD Total_JJ exceptional_JJ items_NNS before_IN taxation_NN 350_CD 192_CD Net_JJ taxation_NN credit_NN 54_CD Total_JJ exceptional_JJ items_NNS after_IN taxation_NN 350_CD 138_CD There_EX were_VBD no_DT exceptional_JJ items_NNS in_IN 2003_CD ._.
As_IN set_VBN out_RP in_IN more_JJR detail_NN in_IN Note_NN 31_CD ,_, the_DT Company_NNP announced_VBD on_IN 20_CD June_NNP 2003_CD a_DT settlement_NN of_IN the_DT US_NNP Department_NNP of_IN Justice_NNP investigation_NN into_IN the_DT US_NNP sales_NNS and_CC marketing_NN practices_NNS for_IN Zoladex_NNP goserelin_NN acetate_NN implant_VBP ._.
Negotiations_NNS towards_IN this_DT settlement_NN were_VBD sufficiently_RB advanced_VBN to_TO recognize_VB an_DT exceptional_JJ charge_NN of_IN $_$ 350m_CD at_IN 31_CD December_NNP 2002_CD ._.
The_DT difference_NN between_IN the_DT final_JJ settlement_NN of_IN $_$ 355m_CD and_CC the_DT 2002_CD exceptional_JJ charge_NN of_IN $_$ 350m_CD amounting_NN to_TO $_$ 5m_CD has_VBZ been_VBN charged_VBN to_TO operating_VBG profit_NN before_IN exceptional_JJ items_NNS in_IN 2003_CD ._.
The_DT integration_NN and_CC synergy_NN program_NN initiated_VBN in_IN 1999_CD was_VBD completed_VBN during_IN 2001_CD ,_, with_IN final_JJ exceptional_JJ charges_NNS of_IN $_$ 202m_CD ,_, principally_RB for_IN manpower_NN related_VBN costs_NNS ,_, IT_PRP costs_NNS and_CC contractors_NNS ._.
4_CD Net_JJ interest_NN 2003 2002 2001_CD $_$ m_CD $_$ m_CD $_$ m_CD Interest_NN receivable_NN and_CC similar_JJ income_NN from_IN investments_NNS Securities_NNPS 21_CD 21_CD 19_CD Short_JJ term_NN deposits_NNS 75_CD 90_CD 179_CD Exchange_NNP gains_NNS 19 61 115 117_CD 199_CD Interest_NN payable_JJ and_CC similar_JJ charges_NNS Loan_NN interest_NN 7_CD 10_CD 32_CD Interest_NN on_IN short_JJ term_NN borrowings_NNS and_CC other_JJ financing_NN costs_NNS 16_CD 51_CD 35_CD Discount_NNP on_IN liability_NN 3_CD 10_CD 15_CD Exchange_NNP losses_NNS 16_CD 12_CD 26_CD 87_CD 94_CD Net_JJ interest_NN receivable_NN 89_CD 30_CD 105_CD
